Beaty v. Food and Drug Administration
853 F. Supp. 2d 30
D.D.C.2012Background
- Plaintiffs are death row inmates challenging FDA/HHS actions permitting import of thiopental for state lethal-injection protocols under the APA and FDCA.
- Dream Pharma Ltd., a London wholesaler, shipped thiopental manufactured in Austria to the United States; Dream was not registered with or listed to the FDA.
- FDA released at least seven shipments of foreign thiopental to various state departments of correction, despite misbranding and lack of FDA approval.
- FDCA provisions make misbranded or new drugs unlawful in interstate commerce; 381(a) requires refusal of admission for such drugs, with a narrow 381(b) exception allowing admission only after compliance and bonding.
- FDA historically documents safety concerns with foreign drugs and has not approved nor reviewed thiopental; plaintiffs argue the agency departed from regulations and its longstanding policy.
- Plaintiffs filed for summary judgment on Counts I and III; defendants moved to dismiss/for summary judgment; the court grants plaintiffs’ motion on Counts I and III.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether FDA’s admission of the thiopental violated the FDCA and APA. | Beaty argues thiopental is misbranded and unapproved, thus should have been refused. | Hamburg/FDCA allows discretion under enforcement principles and argues no mandatory duty to refuse. | Yes; FDA violated the FDCA and thus acted contrary to law. |
| Whether the ‘shall’ language imposes a mandatory duty to refuse admission. | Beaty contends 21 U.S.C. § 381(a) mandates refusal of misbranded/unapproved drugs. | FDA contends ‘shall’ has limited applicability and may permit discretion. | Mandatory duty to refuse admission; statute imposes a clear obligation. |
| Whether plaintiffs have standing to challenge FDA’s action. | Increased risk of improper anesthesia during executions constitutes injury-in-fact. | FDA actions are not shown to cause a concrete injury. | Plaintiffs have Article III standing based on substantial risk of harm in executions. |
| Whether Heckler v. Chaney controls the review of FDA’s decision to admit/ignore thiopental. | Heckler does not control because here the issue is following a statutory directive, not prosecutorial discretion. | Agency discretion on enforcement should be presumptively unreviewable under Heckler. | Heckler does not control; there is a meaningful standard under §381(a) to review the action. |
Key Cases Cited
- Lujan v. Defenders of Wildlife, 504 U.S. 555 (1992) (standing requires concrete injury and causation)
- NRDC v. EPA, 464 F.3d 1 (D.C. Cir. 2006) (injury-in-fact can be increased risk of harm)
- Mountain States Legal Found. v. Glickman, 92 F.3d 1228 (D.C. Cir. 1996) (standing where risk is severe may be modest)
- Public Citizen, Inc. v. National Highway Traffic Safety Admin., 489 F.3d 1279 (D.C. Cir. 2007) (injury-in-fact requires modest increments of risk for severe harm)
- Heckler v. Chaney, 470 U.S. 821 (1985) (enforcement discretion generally not reviewable; not controlling here)
- Jama v. Immigration & Customs Enforcement, 543 U.S. 335 (2005) (conceptual guidance on interpreting ‘shall’ vs ‘may’)
- Zivotofsky v. Sec’y of State, 571 F.3d 1227 (D.C. Cir. 2009) (interpretation of mandatory commands in statutes)
- Wash. Legal Found. v. Friedman, 13 F. Supp. 2d 51 (D.D.C. 1998) (purpose of FDCA and public health safeguards)